Alpha Tau Medical Share Price Today

Alpha Tau Medical to join TASE TA-90 and TA-125 indices on November 5

Alpha Tau Medical shares join TA-90 and TA-125 indices effective November 5, 2026. Company becomes one of only three biomedical firms in the TA-125 index. Dual listed on Nasdaq and TASE since August 2026 under symbol DRTS. CEO Uzi Sofer expects increased visibility and liquidity from index inclusion.

Alpha Tau Medical secures FDA approval to expand US REGAIN trial

FDA approves IDE supplement allowing enrollment of up to 20 patients in REGAIN trial. Patient cap doubled from previous limit of 10 at three U.S. academic centers. Expanded data aims to support market submission for recurrent glioblastoma therapy. Abstract accepted for presentation at SNO Annual Meeting in November 2026.

Alpha Tau completes 48-patient enrollment in pancreatic cancer pilot study

Alpha Tau enrolled 48 patients in its IMPACT pancreatic cancer pilot study. Enrollment tripled from the original target of 12 patients over three expansions. Therapy delivered as one-time add-on to standard first-line chemotherapy. Initial data release targeted for early 2027 to inform pivotal study design.

Alpha Tau Medical Reports H1 2026 Results Amid Major Clinical and Commercial Milestones

Alpha Tau Medical reported a net loss of $68.8 million ($0.76/share) for the six months ended June 30, 2026, versus $18.8 million ($0.25/share) in H1 2025, driven largely by $41.4 million in financial expenses from warrant remeasurement. The company closed a major strategic collaboration with Tolmar, securing a $20 million equity investment at a 25% premium and $15 million for U.S. manufacturing, plus up to $161.5 million in milestone payments. Key clinical achievements included 100% local disease control in the REGAIN glioblastoma trial, completion of ReSTART enrollment with 88 patients, and a 100% objective response rate in the head and neck cancer combination study with pembrolizumab.

HC Wainwright reiterates Buy on Alpha Tau Medical

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating for Alpha Tau Medical. The firm maintains a price target of $15.

Alpha Tau treats first glioblastoma patient in Israel

Alpha Tau Medical Ltd. successfully treated the first glioblastoma patient in Israel using Alpha DaRT at Hadassah University Medical Center. The procedure, led by Prof. Yigal Shoshan, utilized a proprietary brain applicator and real-time navigation. This marks the first Alpha DaRT glioblastoma treatment outside the US.